Can Fite Biopharma Ltd ADR CANF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.32
- Day Range
- $3.22–3.40
- 52-Week Range
- $2.56–21.00
- Bid/Ask
- $3.23 / $3.42
- Shares Outstanding
- 2.14M
- Market Cap
- $7.28M
- Volume/Avg
- 32,895 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.68
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.canfite.com
Valuation
|
Metric
|
CANF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.80 |
Price/Sales | 7.68 |
Price/Cash Flow | — |
Price/Earnings
CANF
Financial Strength
|
Metric
|
CANF
|
|---|---|
Quick Ratio | 3.13 |
Current Ratio | 3.46 |
Interest Coverage | — |
Quick Ratio
CANF
Profitability
|
Metric
|
CANF
|
|---|---|
Return on Assets (Normalized) | −107.48% |
Return on Equity (Normalized) | −186.21% |
Return on Invested Capital (Normalized) | −188.52% |
Return on Assets
CANF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|QFDBg?Q | LOCK|!XR& | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|x%hF<#m | LOCK|q&%G& | $71B | |||
| argenx SE ADR
ARGX
| LOCK|<v$r<S | LOCK|Z<y | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@q?kq@ | LOCK|cW | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|k@k?wd | LOCK|HR$Fv | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!^<Cq<?% | LOCK|#<K!% | $26B | |||
| Moderna Inc
MRNA
| LOCK|K>#j>! | LOCK|^h | $25B | |||
| Incyte Corp
INCY
| LOCK|myVrJ?d | LOCK|zRq | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|<!%z>^ | LOCK|>fn | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|M#p^!?B | LOCK|V>d | $16B |
United States